Sinphar Pharmaceutical Co Stock Last Dividend Paid
| 1734 Stock | TWD 31.25 0.10 0.32% |
Sinphar Pharmaceutical Co fundamentals help investors to digest information that contributes to Sinphar Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Sinphar Stock. The fundamental analysis module provides a way to measure Sinphar Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sinphar Pharmaceutical stock.
Sinphar |
Sinphar Pharmaceutical Co Company Last Dividend Paid Analysis
Sinphar Pharmaceutical's Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Current Sinphar Pharmaceutical Last Dividend Paid | 0.2 |
Most of Sinphar Pharmaceutical's fundamental indicators, such as Last Dividend Paid, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinphar Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, Sinphar Pharmaceutical Co has a Last Dividend Paid of 0.2. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The last dividend paid for all Taiwan stocks is notably lower than that of the firm.
Sinphar Last Dividend Paid Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinphar Pharmaceutical's direct or indirect competition against its Last Dividend Paid to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sinphar Pharmaceutical could also be used in its relative valuation, which is a method of valuing Sinphar Pharmaceutical by comparing valuation metrics of similar companies.Sinphar Pharmaceutical is currently under evaluation in last dividend paid category among its peers.
Sinphar Fundamentals
| Return On Equity | 0.0444 | |||
| Return On Asset | 0.0207 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 6.26 B | |||
| Shares Outstanding | 167.72 M | |||
| Shares Owned By Insiders | 20.27 % | |||
| Shares Owned By Institutions | 1.49 % | |||
| Price To Earning | 536.84 X | |||
| Price To Book | 1.88 X | |||
| Price To Sales | 2.15 X | |||
| Revenue | 2.43 B | |||
| Gross Profit | 888.71 M | |||
| EBITDA | 109.64 M | |||
| Net Income | (38.13 M) | |||
| Cash And Equivalents | 937.43 M | |||
| Cash Per Share | 5.59 X | |||
| Total Debt | 1.49 B | |||
| Debt To Equity | 51.50 % | |||
| Current Ratio | 2.25 X | |||
| Book Value Per Share | 17.41 X | |||
| Cash Flow From Operations | 135.54 M | |||
| Earnings Per Share | 1.18 X | |||
| Number Of Employees | 26 | |||
| Beta | 0.79 | |||
| Market Capitalization | 5.4 B | |||
| Total Asset | 6.22 B | |||
| Retained Earnings | 237 M | |||
| Working Capital | 1.28 B | |||
| Current Asset | 2.28 B | |||
| Current Liabilities | 999 M | |||
| Z Score | 1.8 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 1.48 % | |||
| Net Asset | 6.22 B | |||
| Last Dividend Paid | 0.2 |
About Sinphar Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sinphar Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sinphar Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sinphar Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sinphar Stock Analysis
When running Sinphar Pharmaceutical's price analysis, check to measure Sinphar Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinphar Pharmaceutical is operating at the current time. Most of Sinphar Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Sinphar Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinphar Pharmaceutical's price. Additionally, you may evaluate how the addition of Sinphar Pharmaceutical to your portfolios can decrease your overall portfolio volatility.